Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 18/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23220309 | 0.98 | GLS (0.54) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL23220337 | 0.95 | GLS (0.54) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL23220315 | 0.92 | GLS (0.49) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL23220293 | 0.91 | NPC1 (0.54) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL28568225 | 0.91 | RAB9A (0.53) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL19003801 | 0.86 | NPC1 (0.50) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL19003738 | 0.85 | NPC1 (0.49) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL23220326 | 0.85 | NPC1 (0.49) | GLSNPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL28568230 | 0.85 | RAB9A (0.65) | NPC1RAB9ASMN1; SMN2GSK3B | |
| SCHEMBL23220320 | 0.84 | KMT2A (0.57) | NPC1RAB9ASMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | HANGZHOU JENNIFER BIOTECH CO LTD (CN) | 2021-04-13 | — | — | US | disclosed |
| WO-2017101793-A1 | 1, 3, 4-SELENADIAZOLE COMPOUNDS WITH PHARMACOLOGICAL ACTIVITY | HANGZHOU JENNIFER BIOTECH CO., LTD. (CN) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975048-B2 | Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity | GPX4, GPX1, SELENOI | GLS 54/4885NPC1 3453/4885RAB9A 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.